Dr. Biran on New Agents and Combos in Relapsed Multiple Myeloma

Noa Biran, MD
Published: Wednesday, Jul 10, 2019



Noa Biran, MD, physician, John Theurer Cancer Center, discusses new agents and combinations being studied for relapsed multiple myeloma.

Many large phase III trials have shown improvement in patients with relapsed multiple myeloma in terms of progression-free survival (PFS) or overall survival, according to Biran. Isatuximab, a monoclonal antibody to CD38, has been shown in a large randomized phase III study in combination with pomalidomide (Pomalyst) and dexamethasone to significantly improve overall response rate and PFS compared with pomalidomide and dexamethasone alone in patients with ≥2 prior lines of therapy. Due to these results, Biran predicts isatuximab will soon be on the market as another monoclonal antibody.

In early-stage trials, researchers are studying iberdomide (CC-220), an oral agent that’s showing in combination with dexamethasone to have significant activity in patients with heavily pretreated disease. Additionally, the anti-BCMA bi-specific T-cell engager antibody construct AMG 420 is showing significant activity, even as a single agent.
SELECTED
LANGUAGE


Noa Biran, MD, physician, John Theurer Cancer Center, discusses new agents and combinations being studied for relapsed multiple myeloma.

Many large phase III trials have shown improvement in patients with relapsed multiple myeloma in terms of progression-free survival (PFS) or overall survival, according to Biran. Isatuximab, a monoclonal antibody to CD38, has been shown in a large randomized phase III study in combination with pomalidomide (Pomalyst) and dexamethasone to significantly improve overall response rate and PFS compared with pomalidomide and dexamethasone alone in patients with ≥2 prior lines of therapy. Due to these results, Biran predicts isatuximab will soon be on the market as another monoclonal antibody.

In early-stage trials, researchers are studying iberdomide (CC-220), an oral agent that’s showing in combination with dexamethasone to have significant activity in patients with heavily pretreated disease. Additionally, the anti-BCMA bi-specific T-cell engager antibody construct AMG 420 is showing significant activity, even as a single agent.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x